Login to Your Account



Seeking to be a Global Rare Disease Company

Synageva Kicks into High Gear with its $156M Public Offering

By Jennifer Boggs
Managing Editor

Thursday, September 26, 2013
In its fourth substantial public offering in two years, Synageva Biopharma Corp. padded its balance sheet with a $155.7 million to accelerate its aspirations of becoming a global rare disease company replete with burgeoning pipeline programs, manufacturing and commercial infrastructure.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription